Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Even though Eisai’s Halaven showed an unprecedented overall survival effect in a very tough-to-treat breast cancer population, the drug appears to have flopped in a head-to-head study against Xeloda in an earlier line of therapy. Nevertheless, Eisai vows to pursue a regulatory filing that would expand the drug’s label, as planned.